Acid-related upper endoscopy findings in patients with diabetes versus non-diabetic patients.
BACKGROUND
The relationship between diabetes, GERD symptoms and acid-related mucosal damage has not been well studied.


OBJECTIVE
To better quantify risk of acid-related mucosal damage among patients with and without diabetes.


METHODS
A prospective study using 10 sites from the Clinical Outcomes Research Initiative (CORI) National Endoscopy Database surveyed patients undergoing EGD by telephone within 30 days on medical history, symptoms and demographics. Varices and feeding tube indications were excluded. Acid-related damage was defined as any of these findings recorded in CORI: Barrett's esophagus; esophageal inflammation (unless non-acid-related etiology); healed ulcer, duodenal, gastric or esophageal ulcer; stricture; and mucosal abnormality with erosion or ulcer.


RESULTS
Of 1,569 patients, 16% had diabetes, 95% being type 2. Diabetic patients were significantly more likely to be male, older and have a higher body mass index, and less likely to report frequent heartburn and non-steroidal anti-inflammatory drug use. No significant differences were found in acid reflux and proton pump inhibitor (PPI) use between groups. In unadjusted analyses, diabetic patients had a similar risk for acid-related damage than non-diabetic patients (OR 1.09; 95% CI: 0.83, 1.42) which persisted after adjusting for gender, age, acid reflux, acid indication and PPI use (OR 1.04; 95% CI: 0.79, 1.39).


CONCLUSIONS
No difference in risk of acid-related mucosal damage was found, even after adjustment for potential confounders. Our data do not support the need for a lower threshold to perform endoscopy in diabetic patients.
Holub
Jennifer L
JL
CORI-OHSU Department of Gastroenterology, Oregon Health & Science University, CH15C, Portland, OR 97239, USA. holubj@ohsu.edu
Silberg
Debra G
DG
Michaels
Leann C
LC
Williams
J Lucas
JL
Morris
Cynthia D
CD
Eisen
Glenn
G
D000368:Aged; D001471:Barrett Esophagus / Q000453:epidemiology / Q000473:pathology; D003430:Cross-Sectional Studies; D003922:Diabetes Mellitus, Type 1 / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology*; D016099:Endoscopy, Gastrointestinal; D004947:Esophagus / Q000473:pathology; D005260:Female; D005744:Gastric Acid; D005753:Gastric Mucosa / Q000473:pathology; D005764:Gastroesophageal Reflux / Q000453:epidemiology* / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D012307:Risk Factors; D014456:Ulcer / Q000453:epidemiology / Q000473:pathology
Am J Gastroenterol. 1999 Apr;94(4):919-24
10201457
World J Gastroenterol. 2008 May 28;14(20):3212-7
18506928
Am J Gastroenterol. 1987 Sep;82(9):840-3
2820221
Arch Intern Med. 1987 Aug;147(8):1477-80
3632153
Aliment Pharmacol Ther. 2001 Jul;15(7):981-7
11421873
Gastrointest Endosc. 2008 Mar;67(3):489-96
18179793
J Gastroenterol. 2008;43(1):27-31
18297432
World J Gastroenterol. 2008 Feb 7;14(5):709-12
18205259
Gastroenterology. 2004 Jun;126(7):1692-9
15188164
Hepatogastroenterology. 2007 Mar;54(74):643-8
17523341